Nurix Therapeutics (Nurix Therapeutics) EV-to-EBIT : -3.43 (As of Apr. 29, 2024)

Nurix Therapeutics EV-to-EBIT Chart

Nurix Therapeutics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBIT	Get a 7-Day Free Trial															-0.98	-1.27	-1.02	-0.29	-2.49

Competitive Comparison of Nurix Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Nurix Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nurix Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's EV-to-EBIT falls into.

Nurix Therapeutics EV-to-EBIT Calculation

Nurix Therapeutics's EV-to-EBIT for today is calculated as:

Nurix Therapeutics's current Enterprise Value is $539.96 Mil.
Nurix Therapeutics's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics  (NAS:NRIX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nurix Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Nurix Therapeutics's Enterprise Value for the quarter that ended in Feb. 2024 was $392.00 Mil.
Nurix Therapeutics's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nurix Therapeutics (Nurix Therapeutics) Business Description